Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.

[1]  P. Ridker,et al.  Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.

[2]  J. Manson,et al.  Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial , 2005, Circulation.

[3]  A. Moss,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[4]  B. Cohen,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[5]  Paul Schoenhagen,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.

[6]  G. Hitman,et al.  Association between fasting glucose and C-reactive protein in middle-aged subjects. , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[7]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[8]  J. Griffith,et al.  Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. , 2005, JAMA.

[9]  A. Kitabatake,et al.  Can Exercise Training With Weight Loss Lower Serum C-Reactive Protein Levels? , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[10]  R. Marfella,et al.  Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. , 2004, JAMA.

[11]  B. Nicklas,et al.  Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. , 2004, Diabetes care.

[12]  K. Shimada,et al.  Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. , 2004, Circulation.

[13]  F. Fabris,et al.  Body fat and C-reactive protein levels in healthy non-obese men. , 2004, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[14]  C. Lavie,et al.  Reduction in C-reactive protein through cardiac rehabilitation and exercise training. , 2004, Journal of the American College of Cardiology.

[15]  C. Roberts,et al.  Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. , 2004, Metabolism: clinical and experimental.

[16]  A. Jardine,et al.  Fluvastatin inhibits raft dependent Fcγ receptor signalling in human monocytes , 2004 .

[17]  Tzung-Dau Wang,et al.  Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. , 2004, The American journal of cardiology.

[18]  Thomas Weber,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[19]  A. Jardine,et al.  Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. , 2004, Atherosclerosis.

[20]  Tzung-Dau Wang,et al.  Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. , 2003, Atherosclerosis.

[21]  W. Koenig,et al.  Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). , 2003, European heart journal.

[22]  P. Sager,et al.  Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.

[23]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[24]  J. Kampert,et al.  Associations Between Cardiorespiratory Fitness and C-Reactive Protein in Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[25]  S. Haffner,et al.  Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.

[26]  Deepak L. Bhatt,et al.  Need to test the arterial inflammation hypothesis. , 2002, Circulation.

[27]  D. Mikhailidis,et al.  Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels , 2002, Angiology.

[28]  E. Poehlman,et al.  Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women , 2002, Circulation.

[29]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[30]  U. Laufs,et al.  Targeting Rho in cardiovascular disease. , 2000, Circulation research.

[31]  P. Ridker,et al.  Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.

[32]  G. Shen,et al.  Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[33]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.

[34]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[35]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.